| Assessment Status | Rapid review complete |
| HTA ID | 21063 |
| Drug | Dupilumab |
| Brand | Dupixent® |
| Indication | For adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance. |
| Assessment Process | |
| Rapid review commissioned | 13/12/2021 |
| Rapid review completed | 08/02/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that dupilumab (Dupixent®) not be considered for reimbursement at the submitted price* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
